Late-Onset, preventative, combination treatments: The triple challenge facing the most promising anti-aging research paradigm

摘要

There is no doubt whatsoever that therapies that significantly delayed the onset of age-related ill-health would be by far the most cost-effective category of medicine in history, whether that cost is measured in dollars or in human suffering. It is thus a paradox that so little effort is expended by governments or the private sector in the quest to develop such therapies, as compared to the vast amount spent on the very modestly effective treatments for age-related diseases and disability that we have today or on the equally modest prospective improvements on those treatments that disease-specific researchers aim to develop. I do not claim originality for this observation.